Alpha Tau Medical Aktie - DRTS

Alpha Tau Medical Ltd (DRTS) Aktie

Professionelle Tools für Privatanleger.

Premium

Current Price

9,6738

( -5,99% )

Gebot

9,55

Fragen

9,68

Volumen

1.391.017

9,13 Tagesbereich 10,29

2,81 52-Wochen-Bereich 11,62

Marktkapitalisierung

872,345M

Handelsende

10,29

Handelsbeginn

10,27

Letzte Trade

350

9.6738

(formt)

Letzter Handelszeitpunkt

Finanzvolumen

US$ 13.294.995

VWAP

9,5578

Durchschnittliches Volumen (3 Mio.)

US$ 529.552

Ausgegebene Aktien

90.176.067

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

-16,26

Gewinn pro Aktie (EPS)

-0,67

Erlöse (LTM)

Nettogewinn (LTM)

-56,88M

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprisi... Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel. Mehr anzeigen

Sektor

Healthcare

Branche

Biotechnology & Life Sciences

Website

www.alphatau.com

Hauptsitz

Jerusalem, Israel

Gegründet

Alpha Tau Medical Ltd is listed in the Healthcare sector of the NASDAQ with ticker DRTS. The last closing price for Alpha Tau Medical was US$10,29. Over the last year, Alpha Tau Medical shares have traded in a share price range of US$ 2,81 to US$ 11,62.

Alpha Tau Medical currently has 90.176.067 shares in issue. The market capitalisation of Alpha Tau Medical is US$872,35 million. Alpha Tau Medical has a price to earnings ratio (PE ratio) of -16.26.

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s...

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive...

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local...

Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete...

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the...

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the...

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

First patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at...

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

- Abstract from trial evaluating Alpha DaRT® in combination with pembrolizumab in elderly patients with locally...

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

- 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.4262	-4.2198019802	10.1	11.33	8.86	1840559	10.18461558	CS
4	1.8538	23.7058823529	7.82	11.62	7.7	1316544	10.25737601	CS
12	2.7038	38.7919655667	6.97	11.62	6.3507	659771	9.34111238	CS
26	5.5738	135.946341463	4.1	11.62	3.84	487824	8.38730497	CS
52	6.7438	230.163822526	2.93	11.62	2.81	269953	7.87484892	CS
156	5.0538	109.38961039	4.62	11.62	1.75	120640	6.66503695	CS
260	-1.8762	-16.2441558442	11.55	20.65	1.75	132235	8.07585666	CS

DRTS - Frequently Asked Questions (FAQ)

What is the current Alpha Tau Medical Ltd share price?

The current share price of Alpha Tau Medical Ltd is US$ 9,6738

How many Alpha Tau Medical Ltd shares are in issue?

Alpha Tau Medical Ltd has 90.176.067 shares in issue

What is the market cap of Alpha Tau Medical Ltd?

The market capitalisation of Alpha Tau Medical Ltd is USD 872,35M

What is the 1 year trading range for Alpha Tau Medical Ltd share price?

Alpha Tau Medical Ltd has traded in the range of US$ 2,81 to US$ 11,62 during the past year

What is the PE ratio of Alpha Tau Medical Ltd?

The price to earnings ratio of Alpha Tau Medical Ltd is -16,26

What is the registered address of Alpha Tau Medical Ltd?

The registered address for Alpha Tau Medical Ltd is Kiryat HaMada St. 5, Jerusalem, 9777605

What is the Alpha Tau Medical Ltd website address?

The website address for Alpha Tau Medical Ltd is www.alphatau.com

Which industry sector does Alpha Tau Medical Ltd operate in?

Alpha Tau Medical Ltd operates in the Biotechnology & Life Sciences sector

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Alpha Tau Medical Ltd (DRTS)

Alpha Tau Medical Ltd (DRTS) Aktie

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Alpha Tau Medical Ltd

DRTS Neueste Nachrichten

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

DRTS - Frequently Asked Questions (FAQ)

DRTS Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen